Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%

Contributed by: Business Wire

Logo

Tags

Other Consumer

Health

Consumer

Women

Pharmaceutical

Biotechnology

Organon & Co.

More Like This

Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%

Innovaderm, a Key Collaborator in Clinical and Study Development for Recently Published Phase 1 Atopic Dermatitis Study

Vaccitech Renames as Barinthus Biotherapeutics to Highlight Strategic Evolution into a T Cell Immunotherapy Company Targeting Chronic Infectious Diseases, Autoimmunity, and Cancer

Stapokibart Was Granted Marketing Approval From National Medical Products Administration For The Treatment Of Moderate-to-severe Atopic Dermatitis in Adults

PR Newswire associated0

Venatorx Pharmaceuticals and Menarini Group Enter Commercial Agreement for Cefepime-Taniborbactam in 96 Countries

Almirall to Present New Data on Biologics for Psoriasis and Atopic Dermatitis and Celebrates 80 Years of Innovation at the EADV Congress

Nordic Pharma Group B.V. Through Its Subsidiary Amring Pharmaceuticals Inc., Completes Acquisition of Visant Medical to Launch Novel Therapy for Dry Eye Disease in the United States

Organon & Lilly Enter Commercialization Agreement in Europe for Two Migraine Medicines